Search

Your search keyword '"Marta Lopez Yurda"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Marta Lopez Yurda" Remove constraint Author: "Marta Lopez Yurda"
43 results on '"Marta Lopez Yurda"'

Search Results

1. Gastric and duodenal cancer in individuals with Lynch syndrome: a nationwide cohort studyResearch in context

2. IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

Catalog

Books, media, physical & digital resources

3. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

4. Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma

5. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases

6. Abstract OT2-15-01: COntinue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study

7. Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma

8. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

9. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial

10. IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

11. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma

12. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

13. Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma

14. Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis

15. FOLFOXIRI vs FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E mutated primary tumor: phase III CAIRO5 study

16. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases

17. Prophylactic fibrinogen concentrate administration in surgical correction of paediatric craniosynostosis: A double-blind placebo-controlled trial

18. Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

19. Clinical results of PERICLES: A phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis

20. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer

21. Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database

22. LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

23. Adjuvant photodynamic therapy in head and neck cancer after tumor-positive resection margins

24. Prospective Open-Label Phase II Trial of Individualized Anti-Thymocyte Globulin for Improved T-Cell Reconstitution after Pediatric Allogeneic Hematopoietic Cell Transplantation: The Parachute-Study

25. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

26. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001

27. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only : Results from the SIOP-WT-2001 Registry

28. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

29. Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02)

30. Irradiation of localized squamous cell carcinoma of the nasal vestibule

31. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer

32. Prediction of hearing loss due to cisplatin chemoradiotherapy

33. Long-term hearing loss after chemoradiation in patients with head and neck cancer

34. A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

35. Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

36. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: a long-term follow-up study

37. Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG)

38. Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer

39. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer

40. Irradiation of localized squamous cell carcinoma of the nasal vestibule

41. Long-term hearing loss after chemoradiation in patients with head and neck cancer

42. Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?